Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human HRAS Antibodies:
anti-Rat (Rattus) HRAS Antibodies:
anti-Mouse (Murine) HRAS Antibodies:
Go to our pre-filtered search.
Human Polyclonal HRAS Primary Antibody for IF, IHC (p) - ABIN392183
Ma, Liu, Wu, Terada: p66(Shc) restrains Ras hyperactivation and suppresses metastatic behavior. in Oncogene 2010
Show all 2 Pubmed References
Human Polyclonal HRAS Primary Antibody for ELISA, WB - ABIN561363
Ambrosini, Khanin, Carvajal, Schwartz: Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells. in Molecular cancer therapeutics 2014
Suppression of MEK/ERK pathway in senescent cells provides a new strategy for elimination of Ras-expressing cells.
Reduced insulin receptor substrate-1 (IRS-1 (show IRS1 Antibodies)) staining in lung adenocarcinoma tissue microarray displayed a significant survival disadvantage, especially within the Kirsten rat sarcoma viral oncogene (show RAB1A Antibodies) homolog (KRAS) mutant subgroup.
The expression level of KTRAS was positively correlated to the activity of ERK (show EPHB2 Antibodies) pathway in glioma cell proliferation.
Serrated lesions of the appendix are frequently found in serrated polyposis patients and are most commonly of SSA-type morphology, frequently associated with KRAS mutation.
These results suggest that cetuximab treatment in combination with IL-21 adjuvant therapy in patients with EGFR-positive pancreatic cancer results in significant NK cell activation, irrespective of KRAS mutation status, and may be a potential therapeutic strategy
The gene signatures identified a different patient population for MEK (show MAP2K1 Antibodies) inhibitor treatment compared with KRAS mutation testing. The predictive power of the MEK (show MAP2K1 Antibodies) signature should be studied further in clinical trials
MEK inhibition in KRas mutant cells results in activation of ER signaling and prevents the abrogation of signaling through ERK1/2 and p90RSK that is achieved in KRas wild-type EC cells.
Data show that Williams-Beuren syndrome transcription factor (WSTF (show BAZ1B Antibodies)) release was mediated by neuregulin-3 (NRG3 (show NRG3 Antibodies)) following KRASG12V expression in intestinal epithelial cells.
describes practical clinico-pathological specifications to optimize RAS ctDNA determination. Moreover, OncoBEAMtrade mark is useful to monitor RAS in patients undergoing systemic therapy to detect resistance and evaluate the efficacy of particular treatments
our findings provide support for an autocrine signaling loop engaged by oncogenic K-Ras involving ErbB3 (show ERBB3 Antibodies) that contributes to the dedifferentiation of the intestinal epithelium during tumor initiation and progression.
Kita driven expression of oncogenic HRAS leads to early onset and highly penetrant melanoma in zebrafish
Data demonstrate that H-Ras activation is important in the activation of the specific signaling events leading to the accelerated retinal capillary cell apoptosis in hyperglycemic conditions.
Activation of H-Ras and its downstream signaling pathway in the retina and its vasculature could be under the control of superoxide, and H-Ras activation in diabetes can be prevented by inhibiting superoxide accumulation.
Thrombospondin 1 (show THBS1 Antibodies), fibronectin (show FN1 Antibodies), and vitronectin (show VTN Antibodies) are differentially dependent upon RAS, ERK1/2 (show MAPK1/3 Antibodies), and p38 (show MAPK14 Antibodies) for induction of vascular smooth muscle cell chemotaxis.
Loss of wild-type Hras promotes the earliest stages of pancreatic tumorigenesis, and moreover results in more rapid progression of the disease. As such, mechanisms leading to activation of wild-type Ras proteins, including but not limited to redox-dependent reactions, may influence the development of pancreatic cancer.
High HRAS expression is associated with hepatocarcinogenesis.
p21 (show D4S234E Antibodies)-associated inhibition of early-stage malignant progression and the intense expression in papilloma outgrowths, identifies a novel, significant antagonism between p21 (show D4S234E Antibodies) and ras(Ha)/ROCK2 (show ROCK2 Antibodies)/NF-kappaB (show NFKB1 Antibodies) signalling in skin carcinogenesis.these data show that ROCK2 (show ROCK2 Antibodies) activation induces malignancy in ras(Ha)-initiated/promoted papillomas in the context of p53 (show TP53 Antibodies) loss and novel NF-kappaB (show NFKB1 Antibodies) expression
this study shows that retinoic acid stabilizes HRas protein during neurogenesis.
we provide genetic evidence that the wild-type H-Ras and K-Ras proteins are bioequivalent in spite of their different structural and biological properties
loss of one allele of Hras increased the sensitivity of mice to this carcinogen, and this effect was further exacerbated by the loss of the second Hras allele. However, loss of one or both alleles of Nras (show NRAS Antibodies) failed to alter tumor burden, either in the absence or presence of Hras, after exposure to urethane.
H-ras isoform mediates protection against pressure overload-induced cardiac dysfunction in part through activation of AKT (show AKT1 Antibodies)/PI3K signaling pathway.
The long intergenic non-coding RNA CCR492 functions as a let-7 competitive endogenous RNA to de-repress c-Myc (show MYC Antibodies) expression and to promote cell transformation assisted by the constitutively active H-Ras.
these contrasting signatures precisely match those proposed to confer bias toward Hras(CAA61CTA) versus Braf (show BRAF Antibodies)(GTG636GAG) mutations in the original tumor sets. Our findings highlight a novel mechanism whereby exposure history acts through strand-biased mutagenesis to specify activation of preferred oncogenes
The abnormal expression of epidermal cytokeratins suggests that Ha-Ras and Bcl-2 (show BCL2 Antibodies) suppress the terminal differentiation and sustain the stem cell-like features in epidermal keratinocytes
This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region.
GTP- and GDP-binding peptide B
, GTPase HRas
, Ha-Ras1 proto-oncoprotein
, Ras family small GTP binding protein H-Ras
, c-has/bas p21 protein
, c-ras-Ki-2 activated oncogene
, p19 H-RasIDX protein
, transformation gene: oncogene HAMSV
, transforming protein p21
, v-Ha-ras Harvey rat sarcoma viral oncogene homolog
, Transforming protein p21
, neuroblastoma ras oncogene
, v-Ha-ras Harvey rat sarcoma viral oncogene-like protein
, Harvey ras1 protein
, Harvey rat sarcoma viral (v-Ha-ras) oncogene homolog
, ras p21
, small G-protein H-Ras
, GTPase HRas (Transforming protein p21) (H-Ras-1) (c-H-ras)
, Harvey ras 1
, GTPase KRas
, K-Ras 2
, K-ras p21 protein
, PR310 c-K-ras oncogene
, c-Kirsten-ras protein
, cellular c-Ki-ras2 proto-oncogene
, oncogene KRAS2
, v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog
, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
, H-ras 1 protein
, c-Ha-ras p21 protein
, c-Ha-ras transgene
, transforming protein P21
, GTPase NRas
, transforming protein N-Ras